100
Participants
Start Date
October 1, 2018
Primary Completion Date
October 1, 2019
Study Completion Date
January 15, 2020
Memantine Hydrochloride
Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Placebo
Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Salma Mohmed Fahmy, Asyut
Assiut University
OTHER